Journals / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 1

Predictors of poor outcomes in 488 patients with herbinduced liver injury

Pages
47–58
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A long latency, slow recovery, and lowtriglyceride value and platelet counts are important determinants for chronic HILI.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Herb-induced liver injury (HILI) can lead to chronic liver injury, liver transplantation, or even death.
📊
Key Findings & Data:Materials and Methods: Clinical data of 488 patients with HILI were retrospectively analyzed from a Chinese center between January2010 and January 2014.
💡
Conclusion & Impact:A long latency, slow recovery, and lowtriglyceride value and platelet counts are important determinants for chronic HILI.
🔬Design:Modeling & Simulation
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Özet

Background/Aims: Herb-induced liver injury (HILI) can lead to chronic liver injury, liver transplantation, or even death. This study aimed to identify the predictors of poor HILI outcomes, especially chronic HILI. Materials and Methods: Clinical data of 488 patients with HILI were retrospectively analyzed from a Chinese center between January2010 and January 2014. Logistic regression and C-statistic were used to identify risk factors and prognostic models for HILI outcomes. Results: In all patients, 69 (14.1%) developed chronic HILI, and 20 (4.1%) died due to liver injury or underwent liver transplantation. To predict the fatal HILI prognosis, the model for end-stage liver disease (MELD) with a C-statistic of 0.981 (95%CI 0.968-0.995) was better than Hy’s law (C-statistic 0.569; 95%CI 0.449-0.689). The latency, course of peak alanine aminotransferase decreasing ≥50% after discontinuation of herb application, peak triglyceride value, and platelet count at liver injury onset were identified as independent risk factors for chronicity with the adjusted odds ratios of 1.268 (95% confidence interval [CI] 1.034-1.554), 2.303 (95%CI 1.588-3.340), 0.580 (95%CI 0.343-0.978), and 0.183 (95%CI 0.091-0.368), respectively. A prognostic model for chronic HILI based on these four factors yielded the best prediction with a C-statistic of 0.812 (95%CI 0.755-0.868), compared with MELD (C-statistic 0.506; 95%CI 0.431-0.581) and Hy’s law (C-statistic 0.418; 95%CI 0.343-0.492).Conclusion: Model for end-stage liver disease can be used to predict the fatal prognosis of HILI. A long latency, slow recovery, and lowtriglyceride value and platelet counts are important determinants for chronic HILI.

🔖

Cite This Article

ZHU, Y., NIU, M., WANG, J., WANG, R., LI, J., MA, Y., ZHAO, Y., ZHANG, Y., HE, T., YU, S., GUO, Y., ZHANG, F., XIAO, X., SCHULZE, J. (2019). Predictors of poor outcomes in 488 patients with herbinduced liver injury. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 1, 47–58. https://ajindex.com/articles/409284

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Teschke R, Andrade RJ. Drug, herb, and dietary supplement hepatotoxicity. Int J Mol Sci 2016
  2. pii: E1488. [CrossRef] 2. Drug-induced Liver Injury Study Group, Chinese Society of Hepatology, Chinese Medical Association. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int 2017
  3. [CrossRef] 3. Zhu Y, Niu M, Chen J, et al. Hepatobiliary and pancreatic: comparison between Chinese herbal medicine and western medicine-induced liver injury of 1985 patients. J Gastroenterol Hepatol 2016
  4. [CrossRef] 4. Lee WJ, Kim HW, Lee HY, Son CG. Systematic review on herb-induced liver injury in Korea. Food Chem Toxicol 2015
  5. [CrossRef] 5. Branch of Hepatobiliary Diseases China Association of Chinese Medicine, Branch of Chinese Patent Medicine China Association of Chinese Medicine. Guidelines for the diagnosis and treatment of herb-induced liver injury. Chin J Integr Med 2018 Mar 15. doi:10.1007/s11655-018-3000-8. [Epub ahead of print] [CrossRef] 6. Danan G, Teschke R. RUCAM in drug and herb induced liver injury:the update. Int J Mol Sci 2015
  6. pii: E14. [CrossRef] 7. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990
  7. [CrossRef] 8. Kamath PS, Kim WR
  8. Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 2007
  9. [CrossRef] 9. Teschke R. Traditional Chinese medicine induced liver injury. J Clin Transl Hepatol 2014
  10. Melchart D, Hager S, Albrecht S, Dai J, Weidenhammer W, Teschke R. Herbal traditional Chinese medicine and suspected liver injury: a prospective study. World J Hepatol 2017
  11. [CrossRef] 11. Teschke R, Larrey D, Melchart D, Danan G. Traditional Chinese medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Medicines (Basel) 2016
  12. pii: E18. 12. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011
  13. [CrossRef] 13. Teschke R, Danan G. Diagnosis and management of drug-Induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf 2016
  14. [CrossRef] 14. Dağ MS, Aydınlı M, Oztürk ZA, et al. Drug- and herb-induced liver injury: a case series from a single center. Turk J Gastroenterol 2014
  15. [CrossRef] 15. Alempijevic T, Zec S, Milosavljevic T. Drug-induced